ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
June 23, 2021LEO Pharma A/S today announced that the European Commission (EC) has approved Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. -
Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials
December 16, 2019Danish medical dermatology firm Leo Pharma announced that its tralokinumab has achieved all primary and secondary endpoints in three phase 3 studies for the treatment of adults ...
Pharma Sources Insight January 2025
